Literature DB >> 12895440

Transplantation of porcine umbilical cord matrix cells into the rat brain.

M L Weiss1, K E Mitchell, J E Hix, S Medicetty, S Z El-Zarkouny, D Grieger, D L Troyer.   

Abstract

Immune rejection of transplanted material is a potential complication of organ donation. In response to tissue transplantation, immune rejection has two components: a host defense directed against the grafted tissue and an immune response from the grafted tissue against the host (graft vs host disease). To treat immune rejection, transplant recipients are typically put on immunosuppression therapy. Complications may arise from immune suppression or from secondary effects of immunosuppression drugs. Our preliminary work indicated that stem cells may be xenotransplanted without immunosuppression therapy. Here, we investigated the survival of pig stem cells derived from umbilical cord mucous connective tissue (UCM) after transplantation into rats. Our data demonstrate that UCM cells survive at least 6 weeks without immune suppression of the host animals after transplantation into either the brain or the periphery. In the first experiment, UCM cells were transplanted into the rat brain and recovered in that tissue 2-6 weeks posttransplantation. At 4 weeks posttransplantation, the UCM cells engrafted into the brain along the injection tract. The cells were small and roughly spherical. The transplanted cells were positively immunostained using a pig-specific antibody for neuronal filament 70 (NF70). In contrast, 6 weeks posttransplantation, about 10% of the UCM cells that were recovered had migrated away from the injection site into the region just ventral to the corpus callosum; these cells also stained positively for NF70. In our second experiment, UCM cells that were engineered to constitutively express enhanced green fluorescent protein (eGFP) were transplanted. These cells were recovered 2-4 weeks after brain transplantation. Engrafted cells expressing eGFP and positively staining for NF70 were recovered. This finding indicates a potential for gene therapy. In the third experiment, to determine whether depositing the graft into the brain protected UCM cells from immune detection/clearance, UCM cells were injected into the tail vein and/or the semitendinosis muscle in a group of animals. UCM cells were recovered from the muscle or within the kidney 3 weeks posttransplantation. In control experiments, rat brains were injected with PKH 26-labeled UCM cells that had been lysed by repeated sonic disruption. One and 2 weeks following injection, no PKH 26-labeled neurons or glia were observed. Taken together, these data indicate that UCM cells can survive xenotransplantation and that a subset of the UCM cells respond to local signals to differentiate along a neural lineage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12895440     DOI: 10.1016/s0014-4886(03)00128-6

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  27 in total

Review 1.  Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells.

Authors:  Limin Wang; Lindsey Ott; Kiran Seshareddy; Mark L Weiss; Michael S Detamore
Journal:  Regen Med       Date:  2011-01       Impact factor: 3.806

Review 2.  Stem cells in the umbilical cord.

Authors:  Mark L Weiss; Deryl L Troyer
Journal:  Stem Cell Rev       Date:  2006       Impact factor: 5.739

3.  Orthotopic transplantation of immortalized mesencephalic progenitors (CSM14.1 cells) into the substantia nigra of hemiparkinsonian rats induces neuronal differentiation and motoric improvement.

Authors:  Stefan Jean-Pierre Haas; Stanislav Petrov; Golo Kronenberg; Oliver Schmitt; Andreas Wree
Journal:  J Anat       Date:  2007-11-23       Impact factor: 2.610

4.  Neural differentiation of human umbilical cord matrix-derived mesenchymal cells under special culture conditions.

Authors:  Parvin Salehinejad; Noorjahan Banu Alitheen; Abdul Manaf Ali; Abdul Rahman Omar; Mojgan Moshrefi; Batool Motamedi; Seyed Noureddin Nematollahi-Mahani
Journal:  Cytotechnology       Date:  2014-10-26       Impact factor: 2.058

5.  The homing of human cord blood stem cells to sites of inflammation: unfolding mysteries of a novel therapeutic paradigm for glioblastoma multiforme.

Authors:  Kiran Kumar Velpula; Venkata Ramesh Dasari; Jasti S Rao
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

6.  Survival and engraftment of mouse embryonic stem cells in the mammary gland.

Authors:  Hai-Jun Huang; Qi-Shuang Gao; Yun-Guo Qian; Yu-Dan Zhang; Jian Peng; Si-Wen Jiang; Ben Hause
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-12-07       Impact factor: 2.416

7.  Approaches to avoid immune responses induced by repeated subcutaneous injections of allogeneic umbilical cord tissue-derived cells.

Authors:  Bram V Lutton; Patricia S Cho; Erica L Hirsh; Kelly K Ferguson; Alexander G S Teague; John S Hanekamp; Nina Chi; Stephanie N Goldman; Darin J Messina; Stuart Houser; Beow Y Yeap; Sicco H Popma; David H Sachs; Christene A Huang
Journal:  Transplantation       Date:  2010-09-15       Impact factor: 4.939

8.  TGF-beta binding in human Wharton's jelly.

Authors:  Andrzej Małkowski; Krzysztof Sobolewski; Stefan Jaworski; Edward Bańkowski
Journal:  Mol Cell Biochem       Date:  2008-01-24       Impact factor: 3.396

9.  The stem cell debate continues: the buying and selling of eggs for research.

Authors:  F Baylis; C McLeod
Journal:  J Med Ethics       Date:  2007-12       Impact factor: 2.903

10.  Combination of stem cell mobilized by granulocyte-colony stimulating factor and human umbilical cord matrix stem cell: therapy of traumatic brain injury in rats.

Authors:  Mehrdad Bakhtiary; Mohsen Marzban; Mehdi Mehdizadeh; Mohammad Taghi Joghataei; Samideh Khoei; Mahdi Tondar; Vahid Pirhajati Mahabadi; Bahareh Laribi; Asghar Ebrahimi; Seyed Jafar Hashemian; Navid Modiry; Soraya Mehrabi
Journal:  Iran J Basic Med Sci       Date:  2011-07       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.